The Technology Centre of New Jersey
675 U.S. Route One, South
About Advaxis, Inc.Advaxis is a clinical-stage biotechnology company developing cancer immunotherapies that enlist the body’s own immune system to fight cancer.
CEO: Daniel O’Connor
CFO: Sara Bonstein
CSO (Scientific): Robert Petit
Please click here for Advaxis job opportunities.
Please click here for clinical trial information.
Tweets by Advaxis
465 articles with Advaxis, Inc.
Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results
Advaxis, Inc. today announced a new prioritization of its product portfolio, as well as financial results and business highlights for the three months ended April 30, 2018.
Effective June 6, 2018.
Findings will be highlighted in a poster discussion at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago, on Saturday, June 2, from 4:45 pm to 6:00 p.m. CDT
Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take place on Thursday, June 7, 2018.
Preclinical findings were discussed in poster presentations at the recent American Association for Cancer Research (AACR) Annual Meeting.
4/23/2018After nearly a year without a permanent chief executive officer Advaxis, Inc. has a new hand on the wheel. This morning the company announced Kenneth A. Berlin will take over the helm of the company as president and CEO effective immediately.
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
Lm platform targets common mutations in tumor driver genes.
Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
The discussion will be presented and lead by author and principle investigator of the study, Mark Stein, MD, medical oncologist at Columbia University Medical Center.
The FDA placed a hold on Advaxis' Phase I/II trial following the death of a patient.
The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company management will present at the following upcoming March 2018 conferences
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
Advaxis, Inc. announces financial results for the three months ended January 31, 2018 and provides a business update.
Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results for the three months ended January 31, 2018, to take place on Monday, March 12, 2018.
Advaxis, Inc. announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Advaxis Submits Conditional MAA for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in EU
The MAA submission is centered around the encouraging results from the GOG-0265 study.
Advaxis Announces Publication of Phase II Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer
Advaxis announces that data from an earlier Phase 2 clinical study of axalimogene filolisbac (ADXS11-001) as a treatment for persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) was accepted for publication in the May edition of peer-reviewed International Journal of Gynecological Cancer.
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
Advaxis announces that three abstracts highlighting the Company’s Listeria-based immunotherapy in combination with antibody-based immunotherapies have been accepted for poster presentation at the upcoming 2018 Keystone Symposia on Cancer Immunotherapies: Combinations (C5) taking place March 23-27, 2018 at the Queen Elizabeth Fairmont in Montreal.
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology
Advaxis today announces that data from the investigator-initiated study evaluating the Company’s proprietary Lm-based antigen delivery product.
As of October 31, 2017, Advaxis had cash, cash equivalents and investments of $70.9 million.
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017
The conference call and live audio webcast will begin at 10:00 a.m. Eastern time on Thursday, December 21, 2017.